Efficacy of Low-Dose Rituximab in a Refractory Acquired Factor VIII Inhibitor Case Secondary to Pemphigus

Publisher： Karger

E-ISSN： 1421-9662|127|1|20-22

ISSN： 0001-5792

Source： Acta Haematologica, Vol.127, Iss.1, 2011-10, pp. : 20-22

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Acquired Factor VIII Inhibitor in a Patient with Dermatomyositis – A Case Study

By  

Acta Haematologica, Vol. 119, Iss. 1, 2008-01 ,pp. : 8-11

Karger

Access to resources Recommend Favorite

Acquired Inhibitor to Factor VIII in a Nonhemophiliac Patient

By  

JOURNAL OF AMERICAN GERIATRICS SOCIETY, Vol. 34, Iss. 6, 1986-06 ,pp. : 472-474

John Wiley & Sons Inc

Access to resources Recommend Favorite

Low‐dose rituximab and concurrent adjuvant therapy for pemphigus: Protocol and single‐centre long‐term review of nine patients

By  

AUSTRALASIAN JOURNAL OF DERMATOLOGY, Vol. 59, Iss. 1, 2018-02 ,pp. : e47-e52

John Wiley & Sons Inc

Access to resources Recommend Favorite

Life-Threatening Bleeding from Refractory Acquired FVIII Inhibitor Successfully Treated with Rituximab

By  

Acta Haematologica, Vol. 109, Iss. 4, 2003-07 ,pp. : 206-208

Karger

Access to resources Recommend Favorite

Low‐dose chemoimmunotherapy with fludarabine, cyclophosphamide, and rituximab in follicular lymphoma

By  

EUROPEAN JOURNAL OF HAEMATOLOGY, Vol. 94, Iss. 3, 2015-03 ,pp. : 277-278

John Wiley & Sons Inc

Access to resources Recommend Favorite